Shopping Cart
- Remove All
Your shopping cart is currently empty
BTB01303 is a glutamate release inhibitor that targets the high levels of glutamate released by cancer cells, which disrupts normal bone turnover and can lead to cancer-induced bone pain. BTB01303 has the potential to improve cancer-induced bone pain [1].

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks |
| Description | BTB01303 is a glutamate release inhibitor that targets the high levels of glutamate released by cancer cells, which disrupts normal bone turnover and can lead to cancer-induced bone pain. BTB01303 has the potential to improve cancer-induced bone pain [1]. |
| In vitro | BTB01303 inhibits breast cancer cells from releasing high levels of glutamate, alleviating bone pain caused by glutamate-induced disruption of normal bone turnover [1]. |
| Molecular Weight | 324.16 |
| Formula | C15H11Cl2NO3 |
| Cas No. | 652129-89-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.